Torrent Pharma-JB Chemicals merger: key dates 2026

What the NCLT Ahmedabad Bench ordered

The Ahmedabad Bench of the National Company Law Tribunal (NCLT) has directed J.B. Chemicals & Pharmaceuticals Ltd. (transferor) and Torrent Pharmaceuticals Ltd. (transferee) to convene equity shareholder meetings for their proposed scheme of amalgamation. The direction was issued under Sections 230 to 232 of the Companies Act, 2013.

The order was delivered on March 23, 2026, by a Bench comprising Judicial Member Chitra Hankare and Technical Member Dr Velamur G Venkata Chalapathy. It was modified through a corrigendum dated March 24, 2026, and the corrigendum was uploaded to the NCLT website on March 25, 2026.

The Tribunal’s directions formalise the next procedural step in the merger process, moving the scheme forward to shareholder voting through a court-convened meeting framework.

Meetings to be held within 45 days, via video conferencing

In its directions for equity shareholders, the Tribunal observed that the meeting should be convened within 45 days from the date of the order through video conferencing (VC) or other audio-visual means (OVAM). The order also specified a quorum requirement of 30 shareholders.

Both companies are headquartered in Ahmedabad and fall under the jurisdiction of the Registrar of Companies, Gujarat, which sets the regulatory context for filings and procedural compliance.

The Tribunal disposed of the application after issuing its directions, including appointments for meeting oversight.

Appointed date and board approvals already in place

The scheme proposes to merge J.B. Chemicals into Torrent Pharmaceuticals with an appointed date of January 21, 2026. The boards of both companies approved the scheme on June 29, 2025.

Separately, the transaction background in the provided material indicates that Torrent acquired a controlling stake of 46.39% in J.B. Chemicals on January 21, 2026, following regulatory approvals, and that the acquisition was completed in stages between December 2025 and February 2026, reaching 48.8% on a fully diluted basis.

The scheme also states that, upon amalgamation, J.B. Chemicals will dissolve without winding up and its shareholders (other than Torrent) will become shareholders of Torrent.

Creditor meetings dispensed with

The NCLT dispensed with the convening of meetings of secured creditors for both companies based on consent affidavits. J.B. Chemicals reported one secured creditor, while Torrent Pharmaceuticals reported eight secured creditors.

It also dispensed with meetings of unsecured creditors, including lessors, for both companies, as per the corrigendum dated March 24, 2026.

The order also noted that no proceedings or investigations were pending against either company.

Who will run the meeting process

The Tribunal appointed Shri Mahesh Gupta, an independent company secretary, as Chairman of the meetings, with Gunjan Agarwal as the alternate.

In the Torrent shareholder meeting notice details included in the material, meeting officials also include Rajesh Parekh (Membership No. A8073) as scrutinizer and Aishwarya Parekh (Membership No. F13318) as alternate scrutinizer.

These appointments are meant to ensure the voting and reporting process follows prescribed governance standards.

JB Chemicals publishes shareholder meeting notice and e-voting dates

J.B. Chemicals published newspaper advertisements for the notice of the equity shareholders meeting on March 28, 2026, in Indian Express (English, all India editions) and Sandesh (Gujarati, Gujarat edition). The meeting is scheduled for Tuesday, April 28, 2026 at 2:00 p.m. IST and will be held through VC/OVAM.

The cut-off date stated in the notice is Tuesday, April 21, 2026. Remote e-voting is scheduled to open on Friday, April 24, 2026 at 9:00 a.m. IST and close on Monday, April 27, 2026 at 5:00 p.m. IST. E-voting at the meeting will be available for shareholders who did not vote through remote e-voting.

Torrent’s meeting notice and stock exchange filings

Torrent Pharmaceuticals also issued a notice for a shareholder meeting convened by the NCLT, scheduled on April 28, 2026 at 10:00 a.m. IST via VC/OVAM, to consider and approve the scheme of amalgamation.

Torrent filed intimations with BSE Limited and the National Stock Exchange of India Limited on March 28, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. J.B. Chemicals also filed disclosures, with the filing signed by Company Secretary and Vice President – Secretarial Sandeep Phadnis on March 28, 2026.

Shareholders whose names appear in the register of members or beneficial owners as on the cut-off date will be entitled to vote. Physical attendance has been dispensed with due to the VC format, and proxy appointments are not available for the meeting.

Swap ratio, valuation markers, and synergy estimate in circulation

The scheme documentation referenced in the provided content states an exchange ratio of 51 equity shares of Torrent (face value ₹5 each) for every 100 equity shares of J.B. Chemicals (face value ₹1 each).

The merger has been described with an approximate equity valuation of ₹25,689 crore, and Torrent’s earlier acquisition of a 46.39% stake from KKR was stated to be for about ₹11,917 crore. The material also states the merger has secured Competition Commission of India (CCI) approval on October 21, 2025, subject to voluntary modifications.

On potential benefits, the material cites Morgan Stanley projecting cost synergies of ₹300 crore to ₹450 crore following integration activities.

Financial snapshot and capital structure points cited

The scheme summary included financial metrics for FY2025: Torrent Pharmaceuticals reported consolidated revenue of ₹11,516.1 crore and profit after tax of ₹1,911.3 crore, while J.B. Chemicals reported revenue of ₹3,917.5 crore and profit of ₹659.6 crore.

For the nine months ended December 31, 2025, Torrent’s total revenue was stated as ₹9,783 crore, up from ₹8,557 crore in the same period last year.

On capital structure, J.B. Chemicals reported authorised share capital of ₹20.3 crore and paid-up capital of ₹16.05 crore, with over 69,000 equity shareholders. The scheme summary also stated Torrent’s share capital pre-scheme was ₹169.22 crore and that the combined entity’s authorised share capital would increase to ₹255.3 crore post-amalgamation.

Key dates and numbers at a glance

Deal metrics and financials cited in the material

Market impact and what remains pending

The immediate market relevance is procedural: the NCLT framework, VC meetings, and the remote e-voting schedule set a defined route to shareholder decisions. The Tribunal’s decision to dispense with secured and unsecured creditor meetings, based on consent affidavits and the corrigendum, reduces steps in the court-convened process.

However, the material also indicates that beyond the NCLT process, the amalgamation still requires further approvals, including shareholder consent and regulatory clearances from SEBI and stock exchanges. It also notes that any procedural updates from the NCLT and further regulatory steps will be key markers for the completion timeline.

Why the sequence matters

The order and corrigendum show the merger is progressing through formal statutory steps: appointed date, Tribunal directions, meeting notices, and regulated voting. The governance layer is also visible through the named chairperson and scrutinizer appointments, and through stock exchange intimations under Regulation 30.

The numbers disclosed in the scheme and related material highlight why the merger has investor attention: pro forma scale, the share swap ratio, and the cited synergy estimate. But the next concrete trigger remains the outcome of shareholder voting and completion of remaining regulatory conditions.

Conclusion

Torrent Pharmaceuticals and J.B. Chemicals have moved to the shareholder approval stage after NCLT Ahmedabad’s March 23 order and March 24 corrigendum. Equity shareholders will vote on April 28, 2026 through VC/OVAM, with remote e-voting available from April 24 to April 27, 2026. The next updates to track are the meeting results, subsequent filings, and any final clearances required from SEBI and the stock exchanges.